Id3 Knockout in CAR-T Cells for GVHD Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current allogeneic hematopoietic stem cell transplantation (allo-HSCT) therapies face challenges such as graft-versus-host disease (GVHD) and limited antitumor activity due to rapid elimination by the host immune system.

Innovation Solution

Genetically engineering CD3+ T cells to reduce Id3 expression by at least 25% and administering them as an immunotherapy method, which decreases the risk of graft-versus-host reaction while preserving graft-versus-tumor immunity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic T cells are administered for immunotherapy, then graft-versus-tumor immunity is enhanced, but graft-versus-host disease risk increases

Engineering Contradiction:

Improveantitumor activityVSAvoidGVHD risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and removes the harmful component (Id3) from the allogeneic T cells while preserving the beneficial antitumor activity. By specifically knocking out the Id3 gene through CRISPR/Cas9 technology, the invention separates the harmful GVHD-inducing properties from the useful graft-versus-tumor immunity, allowing administration of modified T cells that retain therapeutic efficacy without causing severe host tissue damage

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality modification by specifically altering the Id3 expression level in T cells rather than making global changes to all cellular functions. This targeted genetic modification affects only the specific pathway responsible for GVHD while leaving other important T cell functions intact, creating a localized improvement in safety profile without compromising overall therapeutic capability

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If host immune system eliminates engineered T cells rapidly, then short-term safety is improved, but long-term therapeutic efficacy is reduced

Engineering Contradiction:

Improveimmune eliminationVSAvoidT cell persistence

Core Design Contradiction:

Object-affected harmful factorsVSDuration of action of stationary object

Solution Approach 1:

The patent converts the harmful rapid elimination effect into a beneficial outcome by removing Id3, which paradoxically prevents T cell exhaustion and maintains long-term persistence. The modified T cells with reduced Id3 expression avoid immune-mediated elimination while sustaining therapeutic activity against leukemia, transforming the initial adverse effect into a durable therapeutic advantage

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250041344A1Gene editing methods for modulating expression of id-3, an inhibitor of DNA-binding transcription factors, thereby affecting t-cell function

Publication Date: 2025.02.06 HACKENSACK MERIDIAN HEALTH INC

AI summary

The present disclosure provides gene editing methods for modulating the expression of an inhibitor of DNA-binding E-protein transcription factors, namely Id3, and thereby affecting T cell function. First, it provides experimental evidence that Id3 is critical to the persistence and function of tissue-infiltrating GVHD T cells in a mouse model. Id3 reduces chromatin accessibility (ChrAcc) of transcription factors (TFs) that drive T cell PD-1 transcription, differentiation and dysfunction. Id3 loss increases PD-1 expression and impairs tissue-infiltrating Th1 cells. Second, it provides proof-of-concept that targeting ID3 in human T cells using a CRIPSR/Cas9 knockout (KO) prevents xeno-GVHD but preserves the anti-leukemic activity of chimeric antigen receptor (CAR)-T cells. Third, it provides experimental evidence that ectopic expression of Id3 in engineered human CAR-T cells enhances the ability of these cells to eliminate tumors.